January 7, 2003

Neurochem to present at the 21st Annual JP Morgan H&Q Healthcare Conference.

- Neurochem, Inc. (TSX: NRM) announced today that it will present at the 21st Annual JP Morgan H&Q Healthcare Conference taking place from January 6-9, 2003 at the Westin St. Francis Hotel in San Francisco, CA. Dr. Francesco Bellini, Neurochem's Chairman and CEO, will deliver the presentation on Thursday, January 9, 2003 at 10:00 am (PT). A copy of the Company's presentation will be available on the Neurochem's Web site at http://www.neurochem.com/Investor.htm#Presentation .

During the presentation, Dr. Bellini will highlight recent corporate and clinical advancements that include:

• The completion of patient enrollment in the Company's pivotal Phase II/III trial for Fibrillex™, for the life-threatening orphan disease, secondary amyloidosis,

• The investment of $8 million in Neurochem by Picchio Pharma Inc.,

• The appointment of Dr. Philippe Calais as President of Neurochem, and

• The initiation of Phase II clinical trials for Alzhemed™, for the treatment of Alzheimer's disease, and Cerebril™, for the treatment of hemorrhagic stroke due to cerebral amyloid angiopathy.

About Neurochem

Neurochem is a product-driven, specialty pharmaceutical company which offers a new class of drug candidates to prevent and stop the progression of diseases for which no cure exists. The Company's strong and growing pipeline will meet unmet medical needs and is focused on disorders of the central nervous system and amyloid-related diseases. Neurochem's most advanced product candidate is Fibrillex™, in pivotal Phase II/III clinical development for the treatment of Secondary Amyloidosis, a fatal kidney disease. Two other product candidates in Phase II clinical development are Alzhemed™ for the treatment of Alzheimer's disease and Cerebril™ for Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy. At the pre-clinical development stage, the Company has two potential products targeting Diabetes Type 2 and Epileptic Seizures induced by traumatic brain injury (www.neurochem.com).

All of the statements contained in this news release, other than statements of fact which are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.

For further Information, please contact:
Dr. Lise Hébert
Vice-president, Corporate Communications
lhebert@neurochem.com

275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.